Safety of Allogeneic Hematopoietic Cell Transplantation (HCT) For Patients With Classical Hodgkin Lymphoma (CHL) Treated With Nivolumab
Recruiting in Palo Alto (17 mi)
+2 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Bristol-Myers Squibb
No Placebo Group
Breakthrough Therapy
Trial Summary
What is the purpose of this trial?
An observational database analysis, using existing data of patients diagnosed with Classical Hodgkin Lymphoma.
Research Team
BS
Bristol-Myers Squibb
Principal Investigator
Bristol-Myers Squibb
Eligibility Criteria
Inclusion Criteria
Age greater than or equal to18 years;
First allogeneic HCT for cHL;
Patients with prior autologous HCT for cHL;
See 2 more
Treatment Details
Interventions
- Allogeneic Hematopoietic Cell Transplantation ()
- Nivolumab (Checkpoint Inhibitor)
Participant Groups
2Treatment groups
Experimental Treatment
Group I: Unexposed to nivolumab prior to allogeneic HCTExperimental Treatment1 Intervention
patients who were not treated with nivolumab-based regimen prior to an allogeneic HCT
Group II: Exposed to nivolumab prior to allogeneic HCTExperimental Treatment1 Intervention
patients who were treated with nivolumab-based regimen prior to an allogeneic HCT
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Local Institution - 0001Lawrenceville, NJ
Bristol-Myers SquibbPrinceton, NJ
Center for International Blood and Marrow Transplant ResearchMilwaukee, WI
Loading ...
Who Is Running the Clinical Trial?
Bristol-Myers Squibb
Lead Sponsor
Trials
2731
Patients Recruited
4,127,000+
Headquarters
New York City, USA
Known For
Oncology & Cardiovascular
Top Products
Eliquis, Opdivo, Revlimid, Orencia